Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines.The Company has a platform of gene delivery technologies, which are predominately based on highly engineered viral systems.Latest News09 May 2008Oxford BioMedica Annual General Meeting 09 May 2008Oxford BioMedica Interim Management Statement 21 April 2008Notice of Annual General Meeting InvestorsOxford BioMedica was established in 1995 as a spin out from Oxford University. The company listed on AIM in 1996 and moved to the official list of the London Stock Exchange in 2001. Download2007 Preliminary Results Latest Corporate PresentationShare PriceProductsOxford BioMedica has created a broad pipeline of development candidates that use genes as the direct or indirect mediators of a therapeutic effect. The Company’s advanced development pipeline includes treatments for cancer, Parkinson’s disease and retinopathy. The Company’s early stage development pipeline includes preclinical candidates for Stargardt disease, motor neuron disease, spinal muscular atrophy and AIDS. Cancer Vaccine TrialTRIST is a Phase III clinical trial of Oxford BioMedica’s therapeutic cancer vaccine, TroVax®, in kidney (renal) cancer, which is taking place across approximately 120 centres in USA, Western and Eastern Europe. To find out more visit www.trovax.com |
Website by College Hill - Life Sciences |
